SSPE , detail from standees textbook and article

Reading File

Finding Sources

Searching PubMed

subacute sclerosing panencephalitis

Reading File

Loading Image

I now have all the information needed for a comprehensive answer. The user likely meant Adams and Victor's Principles of Neurology (often abbreviated "Adams & Victor" — commonly called a "standee" style classic reference). Let me compile the full answer.

Subacute Sclerosing Panencephalitis (SSPE)

Overview & Historical Background

SSPE was first described by Dawson in 1934 as "inclusion body encephalitis" and later renamed by Van Bogaert. It is now established as a chronic measles virus infection of the CNS — a rare late complication occurring in immunocompetent individuals. The condition is a rare, chronic, progressive demyelinating disease caused by persistent non-permissive (non-productive) measles virus infection of neurons and glia.

Adams and Victor's Principles of Neurology, 12th Ed. | Bradley and Daroff's Neurology in Clinical Practice | Harrison's 22E

Epidemiology

Parameter	Detail
Incidence	~1 per 1,000,000 children/year (vaccinated populations); up to 5–6/million in unimmunized
Frequency	1 in 100,000–500,000 measles cases
Age	85% aged 5–15 years at diagnosis
Sex	Male:Female ratio 3:1
Latent period	Median 8 years (range 2–12 years) after primary measles
Trigger	Primary measles infection typically before age 2 years

SSPE has practically disappeared in vaccinated populations, though vaccine hesitancy and rising measles cases threaten a resurgence. — Harrison's 22E

Pathogenesis

The virus is defective: aberrant Matrix (M) protein, along with other envelope proteins, interferes with viral assembly and budding. As a result:

The virus cannot form infectious particles and remains intracellular
It spreads cell-to-cell rather than by free virions
This conceals it from immune clearance despite high antibody titers

This explains why SSPE develops in immunocompetent children — the virus is not killed because it is never fully exposed to humoral or cellular immunity. Early infection before age 2, when immune responses are immature, may facilitate initial viral persistence.

— Bradley and Daroff's Neurology in Clinical Practice

Clinical Stages

Stage I — Behavioural/Cognitive

Declining school performance
Personality and mood changes, temper outbursts
Language difficulties, loss of interest in activities

Stage II — Neurological Deterioration

Severe progressive intellectual deterioration
Myoclonus (often "slow" — characteristic of SSPE)
Focal or generalized seizures
Ataxia
Chorioretinitis / visual disturbances
Choreoathetoid or ballistic movements

Stage III — Terminal

Rigidity, hyperactive reflexes, Babinski signs
Optic atrophy, quadriparesis
Autonomic instability
Akinetic mutism, progressive unresponsiveness
Ultimately: decorticate state, coma

Course: Steadily progressive; death within 1–3 years in most cases. Spontaneous remissions occur in ~5%.

Diagnostic Studies

EEG

Pathognomonic pattern: Periodic bursts of 2–3 Hz high-voltage sharp/slow waves occurring at regular intervals of every 3–8 seconds (up to 4–14 seconds apart), against a background of attenuated ("flat") activity. The bursts may last up to 3 seconds.

SSPE EEG — Periodic generalized slow-wave complexes occurring approximately every 12 seconds (Bradley & Daroff's Neurology)

Fig. 78.9 — EEG of a 23-year-old with SSPE showing characteristic periodic slow-wave complexes. (Bradley & Daroff's Neurology in Clinical Practice)

CSF

Acellular (no pleocytosis)
Glucose: normal
Total protein: normal or mildly elevated
Gamma globulin markedly elevated (>20% of total CSF protein)
Oligoclonal IgG bands on gel electrophoresis — measles-virus-specific antibody
Elevated CSF antimeasles antibody — invariably present; consistent with high intrathecal synthesis
CSF/serum antibody ratio confirms intrathecal synthesis

MRI

Early: often normal
As disease progresses: high T2 signal intensity in posterior gray and subcortical white matter
Spreads to periventricular white matter in later stages

Serology

Elevated serum antimeasles antibody titers in all cases

Virology

Measles virus can be cultured from brain by cocultivation techniques
Viral antigen detectable immunocytochemically
Viral genome detectable by in situ hybridization or PCR

Histopathology

Lesions involve the cerebral cortex and white matter of both hemispheres and the brainstem. The cerebellum is usually spared.

Key findings:

Eosinophilic intranuclear and intracytoplasmic inclusion bodies (Cowdry Type A) in neurons and glial cells — the histopathological hallmark
Destruction of nerve cells, neuronophagia
Perivascular cuffing by lymphocytes and mononuclear cells
White matter: degeneration of myelinated fibers (both myelin and axons) + fibrous gliosis → "sclerosing encephalitis"
Electron microscopy: measles nucleocapsids in inclusion-bearing cells

Cerebral cortex in SSPE — Cowdry-type A intranuclear inclusion in a pyramidal neuron plus cigar-shaped cytoplasmic inclusion; Cowdry A inclusions also present in glial cell nuclei. H&E ×350. (Bradley & Daroff's Neurology)

Fig. 78.8 — Cerebral cortex in SSPE: Cowdry-type A intranuclear inclusion and cigar-shaped cytoplasmic inclusion in a pyramidal neuron. Glial inclusions also visible. H&E ×350. (Bradley & Daroff's Neurology in Clinical Practice)

Differential Diagnosis

(Adams & Victor)

Condition	Distinguishing Features
Lipid storage diseases (Tay-Sachs, etc.)	Enzyme assays, cherry-red spot; no measles antibodies
Prion disease (CJD)	Older age, no measles antibodies, 14-3-3 protein in CSF
Schilder-type demyelinating disease	MRI pattern, no measles antibodies
Subacute measles encephalitis (immunosuppressed)	Short interval 1–6 months post measles; no antibody rise; lacks inflammation on histology

Treatment

No definitive curative therapy exists.

Regimen	Details
Isoprinosine (Inosiplex)	100 mg/kg/day orally (max 3 g/day) in 3 divided doses × 6 months; first-line oral agent
Intraventricular interferon-α	Via Ommaya reservoir: starting 100,000 U/m² BSA/day → escalating to 10⁶ U/m²/day over 5 days, then 10⁶ U/m² twice weekly × 6 months
Combination (IFN-α + Isoprinosine)	~30–35% of patients show improvement or stabilization
IV ribavirin + intrathecal IFN-α	Some reported benefit
Levetiracetam	Symptomatic improvement in myoclonus and encephalopathy reported
Subcutaneous IFN-α	Up to 5 million units/day — to treat peripheral reservoirs (lymphoid, glandular tissue)

Laboratory endpoint of treatment: Eradication of detectable measles antigen from CSF.

Risks of treatment: Meningitis, interferon-induced encephalopathy, upper and lower motor neuron toxicity from IFN-α.

Amantadine and inosine pranobex have been tried; effects have not been corroborated in controlled trials. — Adams & Victor

Prevention

Measles vaccination is the only proven prevention.

MMR (measles-mumps-rubella) or MMRV vaccine
First dose: 12–15 months of age
Second dose: 4–6 years of age

SSPE has practically disappeared in countries with high MMR coverage. Vaccine hesitancy is expected to drive a resurgence.

Recent Literature (2023–2024)

Recent systematic reviews highlight specific clinical features of SSPE:

Vision loss in SSPE [Garg et al., 2023 — PMID 37160278]: Chorioretinitis and optic atrophy are significant causes of visual morbidity.
Hyperkinetic and hypokinetic movement disorders in SSPE [Garg et al., 2024 — PMID 38765932]: Myoclonus, dystonia, chorea, and parkinsonism all described.
Movement disorders in SSPE [Garg D et al., 2024 — PMID 38748762]: A broad spectrum of hyperkinetic and hypokinetic movements are recognized, broader than classically taught.

Sources:

Adams and Victor's Principles of Neurology, 12th Edition, p. 774–775
Bradley and Daroff's Neurology in Clinical Practice, pp. 1678–1679
Harrison's Principles of Internal Medicine 22E (2025), p. 1161
Robbins, Cotran & Kumar Pathologic Basis of Disease

This is a shared conversation. Sign in to Orris to start your own chat.